Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$17.11
▼ $0.95 (-5.3%)
Market data updated: 09/20 02:51 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$3.20B
Day Range
$16.96 - $18.14
52-Week Range
$11.92 - $27.31
Beta
—
Next Earnings
02.11.2026
Support
$16.96
Resistance
$27.31
DYN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+22.9% (1Y)
Strengths: 5/24 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Leverage risk
Debt/equity: 0.15
Risk
Biggest negative driver
Daily volatility (ATR)
ATR: 7.4% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
36
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
5d ago · $18.52
Evidence: Panic-selling score jumped from 33 to 75 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
55
Value
50
Momentum
9
Risk
46
Sentiment
38
Fundamental
50
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Dyne Therapeutics has centered on its progress in developing treatments for muscular dystrophy, particularly Duchenne and facioscapulohumeral (FSHD) forms. The company announced FDA clearance for a trial of its DYNE-302 drug in FSHD and plans to present preclinical data for multiple DMD candidates at a major scientific meeting. Analysts adjusted price targets, with RBC raising its estimate to $35 while Morgan Stanley lowered theirs to $45, amid mixed financial results, including a missed earnings estimate in Q2 2026. Investor conferences and stock market activity also featured prominently.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Dyne Therapeutics, Inc.. News trend score: 38. Reason: 7 of the last 20 articles are negative, versus 5 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
43
🎯 Conviction (vs. Emotion)
52
Psychology
82
Fundamentals
50
Technical
9
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-14%
Market Narrative
28
Fundamental Reality
52
Narrative Gap
-24
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests **herding** is dominant, as DYN’s -2.7% decline mirrors peer performance (-1.9%). While panic selling and FOMO scores are elevated, they’re muted by low volatility (0.83x ATR) and neutral RSI (35). The narrative gap (-21) hints at a disconnect between market sentiment (31) and reality (52), possibly signaling cautious herd alignment. The key question: *Is this synchronized movement a temporary peer-driven pullback or a structural shift?*
Updated: 09/05/2026, 03:08 AM
What could change this?
👥 What the crowd believes
"Dyne Therapeutics Receives FDA Clearance to Start Trial of Muscle Disease Treatment"
"Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics with an Overweight and lowers the price target from $47 to $45"
"Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate"
"Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Thorstein Veblen — 13/100
🗣️ Why do they disagree?
The top scores from Mackay, Bagehot and Nelson (100, 100 and 99) reflect that there are no obvious crowd‑mania signs, strong liquidity and a favorable cycle position, leading to uniformly positive assessments. Mid‑range scores from Schwager, Marks and the Marks‑cycle variant (81, 78 and 76) still see a disciplined setup and reasonably priced risk, but are more measured about cycle timing. Graham, Smith, Loeb and Graham‑Enterprising (60, 58, 53, 44) show mixed or insufficient safety margins, indicating value‑oriented frameworks are less convinced. The efficient‑market, Housel, Lynch, Livermore, Veblen and Fisher scores (36 down to 0) highlight concerns about volatility, growth for its own sake, lack of trend and insufficient fundamental data, leading to skeptical views. Thus, based on their documented principles, the model estimates that liquidity‑ and cycle‑focused investors rate DYN favorably, while growth, market‑efficiency and strict value investors are far less enthusiastic.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 90
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 80
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 78
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 62
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 37
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 29
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 27
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-45.9%
ROA
-37.6%
ROIC
—
EPS
-$3.47
Cash
$893.37M
Total Debt
$148.92M
Current Ratio
22.25
Debt/Equity
0.15
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$5.89
Tangible Book Value per Share (Tangible NAV)
$4.54
Sentiment based on basic keywords (not AI) — 5 positive, 8 neutral, 7 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 17.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 9.9.2026
Stocktwits · 9.9.2026
Yahoo · 9.9.2026
MT Newswires · 9.9.2026
Yahoo · 9.9.2026
The Fly · 9.9.2026
The Fly · 9.9.2026
Benzinga · 9.9.2026
MT Newswires · 9.9.2026
MT Newswires · 9.9.2026
Benzinga · 9.9.2026
Benzinga · 9.9.2026
SeekingAlpha · 9.9.2026
Yahoo · 8.9.2026
Barrons.com · 8.9.2026
Yahoo · 8.9.2026
Proactive · 8.9.2026
Dyne Therapeutics, Inc. (DYN) currently has a StockIQ AI score of 36/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
DYN currently scores 36/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
DYN's technical score is 9/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Debt/equity: 0.15; Current ratio: 22.25; Debt/equity: 0.15.
Based on the real signals StockIQ computed: ATR: 7.4% of price; Calmar: 0.24 (3y annualized return 20.2% / max drawdown 85.5%); Return on equity (ROE): -45.9% (negative).
StockIQ has no recorded dividend payment history for DYN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 25 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Kerr Douglas | Open Market Sale | 8.9.2026 | 1,290 | -1,290 | $18.88 |
| Friedl-Naderer Johanna | Open Market Sale | 8.9.2026 | 185 | -185 | $18.88 |
| Cox John | Open Market Sale | 8.9.2026 | 5,658 | -5,658 | $18.88 |
| Friedl-Naderer Johanna | Open Market Sale | 4.9.2026 | 900 | -900 | $24.35 |
| Kerr Douglas | Open Market Sale | 4.9.2026 | 3,745 | -3,745 | $24.35 |
| Rhodes Jason P | Open Market Sale | 14.8.2026 | 1,359,674 | -1,359,674 | $25.00 |
| Rhodes Jason P | Open Market Sale | 14.8.2026 | 478,377 | -478,377 | $25.00 |
| Rhodes Jason P | Open Market Sale | 14.8.2026 | 322,465 | -322,465 | $25.00 |
| Rhodes Jason P | Open Market Sale | 13.8.2026 | 268,354 | -268,354 | $26.20 |
| Rhodes Jason P | Open Market Sale | 13.8.2026 | 94,415 | -94,415 | $26.20 |
| Lucera Erick | Open Market Sale | 13.8.2026 | 1,797 | -1,797 | $26.28 |
| Rhodes Jason P | Open Market Sale | 13.8.2026 | 63,643 | -63,643 | $26.20 |
| Kerr Douglas | Open Market Sale | 13.8.2026 | 1,556 | -1,556 | $26.28 |
| Friedl-Naderer Johanna | Open Market Sale | 13.8.2026 | 226 | -226 | $26.28 |
| Cox John | Open Market Sale | 13.8.2026 | 4,986 | -4,986 | $26.28 |
| Kersten Dirk | Open Market Sale | 27.7.2026 | 256,072 | -256,072 | $25.50 |
| Kersten Dirk | Open Market Sale | 27.7.2026 | 5,388 | -5,388 | $26.04 |
| Kersten Dirk | Open Market Sale | 27.7.2026 | 3,592,184 | -256,072 | $25.50 |
| Kersten Dirk | Open Market Sale | 27.7.2026 | 3,586,796 | -5,388 | $26.04 |
| Rhodes Jason P | Open Market Sale | 7.7.2026 | 5,000 | -5,000 | $23.61 |
| Rhodes Jason P | Open Market Sale | 7.7.2026 | 11,665 | -11,665 | $23.62 |
| Rhodes Jason P | Open Market Sale | 7.7.2026 | 14,844 | -14,844 | $23.62 |
| Rhodes Jason P | Open Market Sale | 7.7.2026 | 49,193 | -49,193 | $23.17 |
| Rhodes Jason P | Open Market Sale | 7.7.2026 | 29,587 | -29,587 | $23.62 |
| Rhodes Jason P | Open Market Sale | 7.7.2026 | 62,543 | -62,543 | $23.17 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
20,790,669 shares short as of 2026-08-31 · vs. 21,970,540 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
54.0% of trading volume this week was short selling, vs. 50.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology